Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24342159 | 1.00 | OPRL1 (0.41) | OPRL1OPRK1HRH1FOLH1OPRD1 | |
| SCHEMBL24342160 | 0.93 | OPRL1 (0.40) | OPRL1OPRK1HRH1OPRD1ALDH1A1 | |
| SCHEMBL22757206 | 0.93 | OPRL1 (0.39) | OPRL1OPRK1HRH1OPRD1ALDH1A1 | |
| SCHEMBL24343361 | 0.85 | OPRL1 (0.39) | OPRL1OPRK1FOLH1OPRD1ALDH1A1 | |
| SCHEMBL27268254 | 0.85 | OPRL1 (0.43) | OPRL1OPRK1FOLH1OPRD1ALDH1A1 | |
| SCHEMBL25881766 | 0.85 | OPRL1 (0.42) | OPRL1FOLH1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25764635 | 0.85 | OPRL1 (0.42) | OPRL1FOLH1OPRD1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23179887 | 0.85 | OPRL1 (0.40) | OPRL1OPRK1HRH1FOLH1OPRD1 | |
| SCHEMBL21916127 | 0.85 | OPRL1 (0.40) | OPRL1OPRK1HRH1FOLH1OPRD1 | |
| SCHEMBL23181088 | 0.85 | OPRL1 (0.40) | OPRL1OPRK1HRH1FOLH1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981434-A1 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-13 | — | — | EP | disclosed |